Pidotimod for Covid-19

Covid-19 was the third leading cause of death in all of 2020, but in December 2020 and the beginning of 2021, the disease suddenly spiked and briefly became the number one cause of death in the United States (u.s.), particularly among those aged 35 years or older even though as of June 30, 2021, about 66% of adults in the u.s. have received at least one Covid-19 vaccine dose. At present, there is no drug to treat Covid-19 that can reduce the morbidity and mortality significantly, which has brought great panic to the society and scientific community. Antiviral agents and immune-modulating treatments are currently being trialed. Searches were conducted in PubMed, ScienceDirect, Google Academic, LitCovid, and MedRxiv for studies published from the beginning of 2000 through April 2021 that tested the clinical uses of pidotimod. Articles were selected prioritizing randomized clinical trials, systematic reviews, and clinical practice guidelines. Research results showed that Immunotherapy proved to be an effective method for fighting against similar viral infections to Covid-19 such as sars-cov, and Middle East respiratory syndrome coronavirus (mers-cov). studies aimed to dilucidated the mechanism of action of pidotimod, as well as randomized clinical trials that evaluate the security and utility of the drug are needed. In this scenario, the administration of Pidotimod could represent a potentially innovative strategy. In conclusion, in patients with Covid-19 without pneumonia, pidotimod could be considered an option, well-tolerated, and associated with a rapid reduction of systemic symptoms of the diseas

Dictamen de estados financieros para efectos fiscales: naturaleza jurídica, evolución e incongruencias

El dictamen de estados financieros para efectos fiscales se vuelve obligatorio para determinados contribuyentes en México desde la década de los noventa; a partir de 2014 se establece como una opción, reconociéndose que implica un costo para los sujetos gobernados. Este trabajo analiza la figura del dictamen para efectos fiscales como parte de las facultades de comprobación, amén de los alcances jurídicos y pragmáticos del cambio de su naturaleza obligatoria a opcional; asimismo, se abordan determinados supuestos desde los que fue creado el Servicio de Administración Tributaria que se contraponen al mecanismo de fiscalización indirecta que constituye el dictamen para efectos fiscales; en adición, se estudia la incidencia de dicho dictamen sobre la figura del dictaminador inde - pendiente, ello dentro del entorno regulatorio empresarial, considerando que las tecnologías de la información dotan a la autoridad exactora de mayores elementos de fiscalización. Todo lo anterior hace cuestionar la viabilidad práctica del dictamen fiscal dentro del marco impositivo mexicano, el cual no es ajeno a las recomendaciones que organismos internacionales brindan sobre la base de experiencias fiscales exitosas. Derechos reservados © 2015 Universidad Nacional Autónoma de México, Facultad de Contaduría y Administración. Este es un artículo de acceso abierto distribuido bajo los términos de la Licencia Creative Commons CC BY-NC-ND 4.0

Pidotimod for Covid-19

Covid-19 was the third leading cause of death in all of 2020, but in December 2020 and the beginning of 2021, the disease suddenly spiked and briefly became the number one cause of death in the United States (u.s.), particularly among those aged 35 years or older even though as of June 30, 2021, about 66% of adults in the u.s. have received at least one Covid-19 vaccine dose. At present, there is no drug to treat Covid-19 that can reduce the morbidity and mortality significantly, which has brought great panic to the society and scientific community. Antiviral agents and immune-modulating treatments are currently being trialed. Searches were conducted in PubMed, ScienceDirect, Google Academic, LitCovid, and MedRxiv for studies published from the beginning of 2000 through April 2021 that tested the clinical uses of pidotimod. Articles were selected prioritizing randomized clinical trials, systematic reviews, and clinical practice guidelines. Research results showed that Immunotherapy proved to be an effective method for fighting against similar viral infections to Covid-19 such as sars-cov, and Middle East respiratory syndrome coronavirus (mers-cov). studies aimed to dilucidated the mechanism of action of pidotimod, as well as randomized clinical trials that evaluate the security and utility of the drug are needed. In this scenario, the administration of Pidotimod could represent a potentially innovative strategy. In conclusion, in patients with Covid-19 without pneumonia, pidotimod could be considered an option, well-tolerated, and associated with a rapid reduction of systemic symptoms of the diseas